Amgen Inc. (AMGN)

NASDAQHealthcare

$343.62
+$12.42 (+3.8%)
Last close

January 21, 2026 at 21:00 UTC

Interactive Chart
AMGN
1H
3H
6H
12H
1D
1W
1M
3M
6M
12M (YTD)
2Y
5Y
All
About Amgen Inc.

Name

Amgen Inc.

CEO

Robert A. Bradway

Industry

Healthcare

Year Founded

1980

Employees

28,000

Amgen Inc. is a biotechnology company focused on discovering, developing, and marketing medicines for serious illnesses across immunology, oncology, cardiometabolic disease, and other therapeutic areas. The company’s expertise spans biologics, targeted therapies, and biosimilars, supported by research platforms in protein engineering and human genetics. Commercial operations include physician education, patient access programs, and collaborations with health systems that emphasize safe and appropriate use of therapies. Amgen distributes products in North America, Europe, and additional regions through a mix of direct channels and partners. Positioned within the healthcare sector, the company’s work reflects the growing role of biotechnology in addressing complex medical needs and advancing precision approaches to treatment.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 11 Buy, 9 Hold, 1 Sell
Buy11
Hold9
Sell1
Fundamentals & Financials
Revenue (TTM)
$35.9B
Net Income (TTM)
$7B
EPS (TTM)
$13.03
ROA (TTM)
7.77%
Current Ratio
1.28
Dividend Yield
0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)
ItemQ3 2025
Revenue$9,557M
Cost of Sales$3,082M
Gross Profit$6,475M
Operating Income$2,526M
Net Income$3,216M
EPS$5.98
Technical Indicators

Amgen Inc.'s Technical Indicators Summary

Amgen's current price near $330 sits just below its 50-day simple moving average, which signals caution despite short- and medium-term averages indicating mild upward momentum. Momentum indicators, including RSI and CCI, suggest a balanced market with neither strong buying nor selling pressure, while the MACD also reflects a neutral stance. The average directional index remains low, pointing to weak trend strength, and volatility is moderate as shown by the ATR. Meanwhile, on-balance volume supports a slight bullish bias, though the absence of a VWAP reading limits intraday context. Overall, these mixed signals contribute to a neutral technical outlook for Amgen at this time.

Buy
11 signals
Neutral
9 signals
Sell
1 signal
Overall: Neutral43% Neutral signals
IndicatorValue
RSI (14)
52.32
Stochastic %K (14, 3, 3)
46.67
CCI (20)
28.45
WPR (14)
-50.89
Momentum (10)
2.77
MFI
44.90
MACD Level (12, 26)
0.53
Bollinger Bands
$320.47 - $337.81
ATR (14)
$7.14 (2.16%)
ADX (14)
11.42
OBV
88,470,400
Simple Moving Averages
$298.68 - $330.63(5 indicators)
Exponential Moving Averages
$306.79 - $328.85(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

AMGN trades decisively stronger, now 3.909% above yesterday’s close at 343.94. An extreme bullish skew shows up in options markets (PCR 0.43). Amgen trades strongly amid sector-wide interest in biotech innovations and strategic collaborations.

Price Change

from $331 close

+$12.94

Trading Volume

Below avg (2.8M)

2.2M

vs S&P 500 Today

Strong Outperformance

+11.36%

52-Week Position

Near highs

97.1%

Updated: January 21, 2026 at 20:04 UTC

Quote Summary
OpenPrevious Close
$329.95$331
Day Range52 Week Range
$329.32 - $343.98$261.43 - $346.38
VolumeAvg. Volume
2.5M2.7M
Market CapP/E Ratio
$184.3B26.5